5月9日周五，再鼎医药（09688.HK）股价盘中大涨5.15%，引发市场关注。这一上涨主要受公司发布的2025年第一季度财报超出市场预期的推动。
根据再鼎医药5月8日晚间公布的财报，公司2025年第一季度总收入达1.06亿美元，同比增长22.19%。其中，产品收入净额为1.057亿美元，同比增长21%，按固定汇率计算增长23%。公司亏损净额从去年同期的5347万美元收窄至4844万美元，经营亏损同比收窄20%。这一业绩表现优于市场预期，显示公司业务持续增长，盈利能力不断改善。
再鼎医药总裁兼首席运营官Josh Smiley在财报中表示，公司正稳步迈向2025年第四季度实现盈利的目标。他还指出，包括贝玛妥珠单抗和KarXT在内的后期管线产品，将与卫伟迦共同推动公司业绩的下一轮增长。这一积极展望也增强了投资者对公司未来发展的信心，进一步推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.